Levosimendan Stada (Levosimendan)

Levosimendan binds to cardiac troponin C, making the heart muscle more responsive to existing calcium, which enhances contractile force without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering after‑load, together improving cardiac output.

The specific dosing regimen for Levosimendan Stada is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. Healthcare professionals calculate the infusion rate and duration according to established guidelines and individual patient needs.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Levosimendan Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without raising intracellular calcium, which may reduce the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel activation, offering a dual mechanism that can be advantageous over agents that solely increase heart rate or contractility.

Levosimendan Stada should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use to maintain stability and sterility.

Levosimendan Stada is administered intravenously by a healthcare professional. The infusion is typically started with a loading dose followed by a continuous maintenance infusion, with the exact rate and duration set by the treating physician based on the patient’s haemodynamic response.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Continuous monitoring of blood pressure, cardiac rhythm, and cardiac biomarkers is essential during therapy to detect and manage these potential complications promptly.

Levosimendan is contraindicated in patients with severe hypotension (systolic blood pressure < 90 mmHg), uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug or its excipients. Caution is also advised in patients with significant hepatic or renal impairment, where dose adjustments may be required.